FDA sees bowel risk in early Glaxo vaccine data

WASHINGTON Wed Sep 22, 2010 9:11pm IST

Related Topics

Stocks

   

WASHINGTON (Reuters) - GlaxoSmithKline Plc's rotavirus vaccine may be linked to a small increase in a life-threatening type of bowel obstruction, U.S. health officials said on Wednesday.

Early data from a study in Mexico suggested infants given the Rotarix vaccine may face a higher chance of an intestinal problem known as intussusception in the 31 days after their first dose, the Food and Drug Administration said on its website.

"Although the results are preliminary and will require further evaluation, FDA approved revised labeling to inform healthcare providers of this finding," the agency said.

Rotavirus is the world's leading cause of severe diarrhea and dehydration in young infants. The benefits of rotavirus vaccines continue to outweigh risks, the FDA said.

Glaxo's rotavirus vaccine sales in 2009 were $440 million globally, including $118 million in the United States.

The British drug company's shares slipped 0.7 percent to $40.06 in morning trading on the New York Stock Exchange.

(Reporting by Lisa Richwine; Editing by Maureen Bavdek)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Biological Medicines

HEALTH SHOWCASE

Walk for Fitness

Walk for Fitness

Walking is the superfood of fitness, experts say.  Full Article 

Ebola Outbreak

Ebola Outbreak

Bill Gates warns Ebola could spread beyond West Africa.  Full Article | Related Story 

Birth Control

Birth Control

Long-acting reversible contraceptives best for teens: pediatricians.  Full Article 

Trial Goal Met

Trial Goal Met

Seattle Genetics and Takeda's cancer drug meets main trial goal.  Full Article 

Childhood Obesity

Childhood Obesity

Antibiotics in infancy may be linked to childhood obesity: study.  Full Article 

MERS Update

MERS Update

Austria reports first MERS case in Saudi national: media.  Full Article 

Sinusitis Drug

Sinusitis Drug

Sanofi-Regeneron drug has positive trial results in chronic sinusitis.  Full Article